NASDAQ:ATXS Astria Therapeutics - ATXS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.28 +0.80 (+6.97%) (As of 03/24/2023 02:52 PM ET) Add Compare Share Share Today's Range$11.21▼$12.3350-Day Range$11.20▼$15.5252-Week Range$2.36▼$16.28Volume187,173 shsAverage Volume233,814 shsMarket Capitalization$206.67 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Astria Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.5% Upside$20.00 Price TargetShort InterestHealthy1.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.56) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector305th out of 989 stocksPharmaceutical Preparations Industry129th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingAstria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Astria Therapeutics has a forecasted upside of 66.5% from its current price of $12.01.Amount of Analyst CoverageAstria Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.44% of the float of Astria Therapeutics has been sold short.Short Interest Ratio / Days to CoverAstria Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Astria Therapeutics has recently decreased by 1.41%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAstria Therapeutics does not currently pay a dividend.Dividend GrowthAstria Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATXS. Previous Next 2.9 News and Social Media Coverage News SentimentAstria Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Astria Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ATXS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Astria Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Astria Therapeutics is held by insiders.Percentage Held by Institutions64.38% of the stock of Astria Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Astria Therapeutics are expected to decrease in the coming year, from ($2.56) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Astria Therapeutics is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Astria Therapeutics is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAstria Therapeutics has a P/B Ratio of 6.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Astria Therapeutics (NASDAQ:ATXS) StockAstria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.Read More Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXS Stock News HeadlinesMarch 23, 2023 | markets.businessinsider.comAstria Therapeutics (ATXS) Receives a Buy from LifeSci CapitalMarch 22, 2023 | businesswire.comAstria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateMarch 24, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 20, 2023 | americanbankingnews.comAstria Therapeutics (ATXS) to Release Quarterly Earnings on WednesdayMarch 8, 2023 | finance.yahoo.comAstria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22ndMarch 6, 2023 | finance.yahoo.comAstria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare ConferenceMarch 4, 2023 | morningstar.comThinking about buying stock in Troika Media, Nio, Lucira Health, Transocean, or Astria Therapeutics?February 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Opko Health (OPK) and Astria Therapeutics (ATXS)March 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 24, 2023 | finance.yahoo.comAstria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual MeetingFebruary 21, 2023 | finance.yahoo.comAstria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual MeetingFebruary 15, 2023 | finance.yahoo.comAstria Therapeutics, Inc. (NASDAQ:ATXS) is a favorite amongst institutional investors who own 55%February 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and SeqLL (SQL)February 8, 2023 | finance.yahoo.comAstria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAEJanuary 27, 2023 | finance.yahoo.comHere's What Could Help Astria Therapeutics, Inc. (ATXS) Maintain Its Recent Price StrengthDecember 27, 2022 | finance.yahoo.comWhat Makes Astria Therapeutics, Inc. (ATXS) a Good Fit for 'Trend Investing'December 27, 2022 | finance.yahoo.comDoes Astria Therapeutics, Inc. (ATXS) Have the Potential to Rally 70% as Wall Street Analysts Expect?December 20, 2022 | seekingalpha.comATXS Astria Therapeutics, Inc.December 19, 2022 | finance.yahoo.comAstria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesDecember 15, 2022 | finance.yahoo.comAstria Therapeutics' Potential Hereditary Angioedema Candidate Shows Encouraging Action In Healthy ParticipantsDecember 15, 2022 | msn.comAstria's hereditary angioedema drug shows promise in healthy people in phase 1 trialDecember 15, 2022 | markets.businessinsider.comAstria Reports Positive Preliminary Results From Phase 1a Trial Of STAR-0215December 15, 2022 | markets.businessinsider.comAstria Therapeutics Prices Offering Of 9.08 Mln Shares At $11.01/ShrDecember 15, 2022 | finance.yahoo.comAstria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy SubjectsDecember 15, 2022 | finance.yahoo.comAstria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common StockNovember 11, 2022 | markets.businessinsider.comLadenburg Thalmann & Co. Reaffirms Their Buy Rating on Astria Therapeutics (ATXS)November 11, 2022 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Astria Therapeutics (ATXS)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astria Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXS Company Calendar Last Earnings11/10/2021Today3/24/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATXS CUSIPN/A CIK1454789 Webwww.catabasis.com Phone(617) 349-1971Fax617-273-2637Employees29Year Founded2008Price Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+74.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-194,910,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-327.59% Return on Assets-41.15% Debt Debt-to-Equity RatioN/A Current Ratio18.40 Quick Ratio18.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book5.77Miscellaneous Outstanding Shares16,830,000Free Float16,153,000Market Cap$193.21 million OptionableNot Optionable Beta0.90 Social Links Key ExecutivesJill C. MilnePresident, Chief Executive Officer & DirectorNoah ClauserChief Financial OfficerMaria C. ManciniVice President-Clinical OperationsAndrew NicholsChief Scientific OfficerChristopher J MorabitoChief Medical OfficerKey CompetitorsAnnexonNASDAQ:ANNXscPharmaceuticalsNASDAQ:SCPHAtai Life SciencesNASDAQ:ATAIZevra TherapeuticsNASDAQ:ZVRAKamadaNASDAQ:KMDAView All CompetitorsInsiders & InstitutionsEAM Investors LLCBought 91,345 shares on 2/15/2023Ownership: 0.543%Silverarc Capital Management LLCBought 81,204 shares on 2/15/2023Ownership: 0.483%Schonfeld Strategic Advisors LLCBought 37,100 shares on 2/15/2023Ownership: 0.220%Morgan StanleyBought 9,120 shares on 2/15/2023Ownership: 0.118%Jane Street Group LLCSold 10,503 shares on 2/15/2023Ownership: 0.065%View All Insider TransactionsView All Institutional Transactions ATXS Stock - Frequently Asked Questions Should I buy or sell Astria Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Astria Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATXS shares. View ATXS analyst ratings or view top-rated stocks. What is Astria Therapeutics' stock price forecast for 2023? 2 analysts have issued twelve-month target prices for Astria Therapeutics' stock. Their ATXS share price forecasts range from $20.00 to $20.00. On average, they anticipate the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 74.2% from the stock's current price. View analysts price targets for ATXS or view top-rated stocks among Wall Street analysts. How have ATXS shares performed in 2023? Astria Therapeutics' stock was trading at $14.89 at the beginning of the year. Since then, ATXS stock has decreased by 22.9% and is now trading at $11.48. View the best growth stocks for 2023 here. When is Astria Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our ATXS earnings forecast. How were Astria Therapeutics' earnings last quarter? Astria Therapeutics, Inc. (NASDAQ:ATXS) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.31. During the same quarter in the previous year, the business posted ($3.36) earnings per share. What ETFs hold Astria Therapeutics' stock? ETFs with the largest weight of Astria Therapeutics (NASDAQ:ATXS) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC). When did Astria Therapeutics' stock split? Astria Therapeutics shares reverse split on the morning of Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What is Astria Therapeutics' stock symbol? Astria Therapeutics trades on the NASDAQ under the ticker symbol "ATXS." Who are Astria Therapeutics' major shareholders? Astria Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Fairmount Funds Management LLC (11.30%), Vivo Capital LLC (9.99%), Driehaus Capital Management LLC (7.95%), Sphera Funds Management LTD. (2.79%), Opaleye Management Inc. (1.55%) and Point72 Asset Management L.P. (1.34%). Insiders that own company stock include Andrew Komjathy and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Astria Therapeutics? Shares of ATXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Astria Therapeutics' stock price today? One share of ATXS stock can currently be purchased for approximately $11.48. How much money does Astria Therapeutics make? Astria Therapeutics (NASDAQ:ATXS) has a market capitalization of $193.21 million. The biotechnology company earns $-194,910,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. How can I contact Astria Therapeutics? Astria Therapeutics' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The official website for the company is www.catabasis.com. The biotechnology company can be reached via phone at (617) 349-1971, via email at info@astriatx.com, or via fax at 617-273-2637. This page (NASDAQ:ATXS) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.